Millipore Sigma Vibrant Logo

440205 LY 83583 - CAS 91300-60-6 - Calbiochem

Übersicht

Replacement Information

Key Spec Table

CAS #Empirical Formula
91300-60-6C₁₅H₁₀N₂O₂

Preis & Verfügbarkeit

Bestellnummer VerfügbarkeitVerpackung St./Pkg. Preis Menge
440205-5MG
Verfügbarkeit wird abgerufen...
Eingeschränkte Verfügbarkeit
Eingeschränkte Verfügbarkeit
Lieferbar 
Produkt wurde eingestellt
Begrenzter Lagerbestand
Bestätigung der Verfügbarkeit erforderlich
    Restmenge: Angebot folgt
      Restmenge: Angebot folgt
      Bitte erfragen
      Kontakt zum Kundenservice
      Contact Customer Service

      Kst.-Ampulle 5 mg
      Preis wird abgerufen...
      Preis nicht abrufbar
      Die Mindestmenge muss ein Vielfaches sein von
      Maximum Quantity is
      Bei Bestätigung Weitere Informationen
      Sie haben () gespart
       
      Bitte erfragen
      Description
      OverviewA cell-permeable, competitive inhibitor of soluble guanylate cyclase (IC50 = 2 µM). Lowers the production of cGMP levels in a wide range of tissues by blocking intracellular Ca2+ release, with negligible effect on cAMP levels. Inhibits nitric oxide-induced smooth muscle relaxation. Shown to inhibit interleukin-1-induced cGMP accumulation in cultured rat aortic vascular smooth muscle cells. Also inhibits neutrophil chemotaxis induced by NO donors.
      Catalogue Number440205
      Brand Family Calbiochem®
      Synonyms6-Anilino-5,8-quinolinequinone
      References
      ReferencesAdachi, R., et al. 2000. Int. J. Immunopharmacol. 22, 855.
      Kawada, T., et al. 1994. Gen. Pharmacol. 25, 1361.
      Beasley, D., et al. 1991. J. Clin. Invest. 87, 602.
      Pandol, S.J., et al. 1990. J. Biol. Chem. 265, 12846.
      Light, D.B., et al. 1989. Science 243, 383.
      Mulsch, A. 1988. J. Pharmacol. Exp. Ther. 247, 283.
      Fleisch, J.H., et al. 1984. J. Pharmacol. Exp. Ther. 229, 681.
      Product Information
      CAS number91300-60-6
      ATP CompetitiveN
      FormReddish purple solid
      Hill FormulaC₁₅H₁₀N₂O₂
      Chemical formulaC₁₅H₁₀N₂O₂
      ReversibleN
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Primary Targetsoluble guanylate cyclase
      Primary Target IC<sub>50</sub>2 µM against soluble guanylate cyclase
      Purity≥98% by HPLC
      Physicochemical Information
      Cell permeableY
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      R PhraseR: 22-36/37/38-45-46-48

      Harmful if swallowed.
      Irritating to eyes, respiratory system and skin.
      May cause cancer.
      May cause heritable genetic damage.
      Danger of serious damage to health by prolonged exposure.
      S PhraseS: 22-26-36/37/39-45

      Do not breathe dust.
      In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
      Wear suitable protective clothing, gloves and eye/face protection.
      In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible).
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Harmful & Carcinogenic / Teratogenic
      Storage +2°C to +8°C
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, store in the refrigerator (4°C). Stock solutions are stable for up to 1 month at 4°C or up to 6 months at -20°C.
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Bestellnummer GTIN
      440205-5MG 04055977186727

      Documentation

      LY 83583 - CAS 91300-60-6 - Calbiochem SDB

      Titel

      Sicherheitsdatenblatt (SDB) 

      LY 83583 - CAS 91300-60-6 - Calbiochem Analysenzertifikate

      TitelChargennummer
      440205

      Literatur

      Übersicht
      Adachi, R., et al. 2000. Int. J. Immunopharmacol. 22, 855.
      Kawada, T., et al. 1994. Gen. Pharmacol. 25, 1361.
      Beasley, D., et al. 1991. J. Clin. Invest. 87, 602.
      Pandol, S.J., et al. 1990. J. Biol. Chem. 265, 12846.
      Light, D.B., et al. 1989. Science 243, 383.
      Mulsch, A. 1988. J. Pharmacol. Exp. Ther. 247, 283.
      Fleisch, J.H., et al. 1984. J. Pharmacol. Exp. Ther. 229, 681.

      Broschüre

      Titel
      Pathways and Biomarkers of Oxidative Stress
      Datenblatt

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision01-February-2024 JSW
      Synonyms6-Anilino-5,8-quinolinequinone
      DescriptionA cell-permeable, competitive inhibitor of soluble guanylate cyclase (IC50 = 2 µM). Lowers the production of cGMP levels in a wide range of tissues by blocking intracellular Ca2+ release, with negligible effect on cAMP levels. Inhibits nitric oxide-induced smooth muscle relaxation. Shown to inhibit interleukin-1-induced cGMP accumulation in cultured rat aortic vascular smooth muscle cells.
      FormReddish purple solid
      CAS number91300-60-6
      Chemical formulaC₁₅H₁₀N₂O₂
      Structure formulaStructure formula
      Purity≥98% by HPLC
      SolubilityAcetone or Ethanol (3 mg/ml)
      Storage +2°C to +8°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, store in the refrigerator (4°C). Stock solutions are stable for up to 1 month at 4°C or up to 6 months at -20°C.
      Toxicity Harmful & Carcinogenic / Teratogenic
      ReferencesAdachi, R., et al. 2000. Int. J. Immunopharmacol. 22, 855.
      Kawada, T., et al. 1994. Gen. Pharmacol. 25, 1361.
      Beasley, D., et al. 1991. J. Clin. Invest. 87, 602.
      Pandol, S.J., et al. 1990. J. Biol. Chem. 265, 12846.
      Light, D.B., et al. 1989. Science 243, 383.
      Mulsch, A. 1988. J. Pharmacol. Exp. Ther. 247, 283.
      Fleisch, J.H., et al. 1984. J. Pharmacol. Exp. Ther. 229, 681.